Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies

American Journal of Hematology

Volumn 89, Issue 4, 2014, Pages 363-368

  Minden, Mark D ^a   Hogge, Donna E ^b   Weir, Scott J ^c   Kasper, Jim ^d   Webster, Debra A ^e   Patton, Lavonne ^e   Jitkova, Yulia ^a   Hurren, Rose ^a   Gronda, Marcela ^a   Goard, Carolyn A ^a   Rajewski, Lian G ^f   Haslam, John L ^f   Heppert, Kathleen E ^f   Schorno, Kevin ^c   Chang, Hong ^g   Brandwein, Joseph M ^a   Gupta, Vikas ^a   Schuh, Andre C ^a   Trudel, Suzanne ^a   Yee, Karen W L ^a   Reed, Gregory A ^c   Schimmer, Aaron D ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d The Leukemia & Lymphoma Society   (United States)

^e Beckloff Associates Inc   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CICLOPIROXOLAMINE; CYTARABINE; DRUG METABOLITE; GLUCURONIDE; NARCOTIC AGENT; SURVIVIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLAST CELL CRISIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; KNEE PAIN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUSPENSION; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; IRON CHELATING AGENTS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NEOPLASM PROTEINS; PYRIDONES; RNA, MESSENGER; RNA, NEOPLASM; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84897399513     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23640     Document Type: Article

References (41)

1. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010;70:2133-2152.
2. Dittmar W, Lohaus G. HOE 296, a new antimycotic compound with a broad antimicrobial spectrum. Laboratory results. Arzneimittelforschung 1973;23:670-674.
3. Kim Y, Schmidt M, Endo T, et al. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. In Vivo 2011;25:887-893.
4. Ma TC, Langley B, Ko B, et al. A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiol Dis 2012;49C:13-21.
5. Song S, Christova T, Perusini S, et al. Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 2011;71:7628-7639.
6. Hoffman BD, Hanauske-Abel HM, Flint A, Lalande M. A new class of reversible cell cycle inhibitors. Cytometry 1991;12:26-32.
7. Clement PM, Hanauske-Abel HM, Wolff EC, et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 2002;100:491-498.
8. Schmidt M, Sievers E, Endo T, et al. Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 2009;144:796-798.
9. Zhou H, Shen T, Luo Y, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer 2010;127:2467-2477.
10. Eberhard Y, McDermott SP, Wang X, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009;114:3064-3073.
11. Balabanov S, Gontarewicz A, Ziegler P, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): A novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007;109:1701-1711.
12. Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp Hematol 2013;41:799-807 e4.
13. Kruse R. La ciclopiroxolamine, inhibiteur énergique fongique. JAMA (French edition) 1991(Suppl. Sept):7-10.
14. Niewerth M, Kunze D, Seibold M, et al. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003;47:1805-1817.
15. Koller CM, Kim Y, Schmidt-Wolf IG. Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide. Anticancer Res 2013;33:2435-2440.
16. Kellner HM, Arnold C, Christ OE, et al. Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration. Arzneimittelforschung 1981;31:1337-1353.
17. Weir SJ, Patton L, Castle K, et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther 2011;36:128-134.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
19. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
21. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
22. U.S. National Institutes of Health. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. (Accessed May 8, 2013).
23. Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer 2013;13:342-355.
24. Yu Y, Gutierrez E, Kovacevic Z, et al. Iron chelators for the treatment of cancer. Curr Med Chem 2012;19:2689-2702.
25. Alpermann HG, Schutz E. Studies on the pharmacology and toxicology of ciclopiroxolamine (author's translation). Arzneimittelforschung 1981;31:1328-1332.
26. Schepers A, Clevers H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb Perspect Biol 2012;4:a007989.
27. Zhu L, Zhou B, Chen X, et al. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase. Biochem Pharmacol 2009;78:1178-1185.
28. Pullarkat V, Sehgal A, Li L, et al. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors. Leuk Res 2012;36:966-973.
29. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010;207:731-750.
30. Myers JM, Antholine WE, Zielonka J, Myers CR. The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress. Toxicol Lett 2011;201:130-136.
31. Gaboriau F, Leray AM, Ropert M, et al. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals 2010;23:231-245.
32. Chao J, Synold TW, Morgan RJ, Jr., et al. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: A California Cancer Consortium Study. Cancer Chemother Pharmacol 2012;69:835-843.
33. Kowol CR, Trondl R, Arion VB, et al. Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans 2010;39:704-706.
34. Richardson D, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 1994;54:685-689.
35. Zanninelli G, Glickstein H, Breuer W, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol 1997;51:842-852.
36. Fukushima T, Kawabata H, Nakamura T, et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 2011;31:1741-1744.
37. Estrov Z, Tawa A, Wang XH, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987;69:757-761.
38. Karp JE, Giles FJ, Gojo I, et al. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res 2008;32:71-77.
39. Odenike OM, Larson RA, Gajria D, et al. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs 2008;26:233-239.
40. Gojo I, Tidwell ML, Greer J, et al. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 2007;31:1165-1173.
41. Yee KW, Cortes J, Ferrajoli A, et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006;30:813-822.